[{"orgOrder":0,"company":"XBiotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"XB2001","moa":"","graph1":"Rheumatology","graph2":"Phase I","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"XBiotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"XBiotech \/ Not Applicable"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"ISRAEL","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"PRX-115","moa":"","graph1":"Rheumatology","graph2":"Phase I","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Protalix BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Protalix BioTherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Urica Therapeutics","sponsor":"Fortress Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dotinurad","moa":"","graph1":"Rheumatology","graph2":"Phase I","graph3":"Urica Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Urica Therapeutics \/ Fortress Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Urica Therapeutics \/ Fortress Biotech"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Arrowhead Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"IRELAND","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"HZN-457","moa":"","graph1":"Rheumatology","graph2":"Phase I","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Horizon Therapeutics \/ Arrowhead Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Horizon Therapeutics \/ Arrowhead Pharmaceuticals"}]